HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
This Quarter Return
+11.99%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$34.7M
AUM Growth
+$34.7M
(+51%)
Cap. Flow
+$10M
Cap. Flow
% of AUM
28.91%
Top 10 Holdings %
Top 10 Hldgs %
99.89%
Holding
11
New
3
Increased
5
Reduced
–
Closed
–
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$3.33M |
| 2 |
GSK
GSK
|
$2.02M |
| 3 |
ProShares UltraShort NASDAQ Biotechnology
BIS
|
$1.46M |
| 4 |
Viking Therapeutics
VKTX
|
$1.42M |
| 5 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
$1.15M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 91.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $7.08M | 20.08% | 100,000 | – | – |
|
|
TYME
2
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $6.56M | 18.59% | 2,075,000 | – | – |
|
|
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $4.83M | 13.7% | 1,313,387 +313,387 | +31% | +$1.15M |
|
|
4
GSK
GSK
$79.9B
| $4.03M | 11.43% | 100,000 +50,000 | +100% | +$2.02M |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $3.33M | 9.45% | +20,000 | New | +$3.33M |
|
|
6
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.47M
| $2.92M | 8.28% | 150,000 +75,000 | +100% | +$1.46M |
|
7
Standard BioTools
LAB
$481M
| $2.68M | 7.6% | 450,000 +39,500 | +10% | +$235K |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $1.55M | 4.38% | 500,000 +50,000 | +11% | +$155K |
|
|
9
Viking Therapeutics
VKTX
$3.04B
| $1.42M | 4.04% | +150,000 | New | +$1.42M |
|
|
ATRS
10
DELISTED
Antares Pharma, Inc.
ATRS
| $258K | 0.73% | +100,000 | New | +$258K |
|
|
SEEL
11
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $39K | 0.11% | 100,000 | – | – |
|